0000000001227867

AUTHOR

S. Camera

showing 3 related works from this author

Euclid preparation XV. Forecasting cosmological constraints for the Euclid and CMB joint analysis

2022

The combination and cross-correlation of the upcoming $Euclid$ data with cosmic microwave background (CMB) measurements is a source of great expectation since it will provide the largest lever arm of epochs, ranging from recombination to structure formation across the entire past light cone. In this work, we present forecasts for the joint analysis of $Euclid$ and CMB data on the cosmological parameters of the standard cosmological model and some of its extensions. This work expands and complements the recently published forecasts based on $Euclid$-specific probes, namely galaxy clustering, weak lensing, and their cross-correlation. With some assumptions on the specifications of current and…

Cosmology and Nongalactic Astrophysics (astro-ph.CO)Cosmic microwave backgroundstatistical [methods]FOS: Physical sciencesAstrophysicscosmic background radiationAstrophysics::Cosmology and Extragalactic AstrophysicsJoint analysiskosmologia01 natural sciencesmethodsNOpimeä aine[PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO]mikroaallotSettore FIS/05 - Astronomia e Astrofisicasurveys0103 physical sciencestszsurvey010303 astronomy & astrophysicsPhysicsmethods: statistical010308 nuclear & particles physicsComputer Science::Information RetrievalmaailmankaikkeusAstrophysics::Instrumentation and Methods for AstrophysicsAstronomy and Astrophysicscross-correlation115 Astronomy Space scienceCosmic background radiation; Large-scale structure of Universe; Methods: statistical; Surveyskosminen taustasäteilySpace and Planetary Sciencemethodlarge-scale structure of Universepimeä energia[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]statisticalAstrophysics - Cosmology and Nongalactic Astrophysics
researchProduct

Euclid preparation - XVII. Cosmic Dawn Survey: Spitzer Space Telescope observations of the Euclid deep fields and calibration fields

2022

Artículo escrito por un elevado núnmero de autores, sólo se referencian el qque aparece en primer lugar, los autores pertenecientes a la UAM y el nombre del grupo de colaboración, si lo hubiere

SAMPLELarge-scale structure of UniverseDATA RELEASEFormationSurveysobservations Dark energy Dark matter Galaxy: formation Large-scale structure of Universe Surveys [Cosmology]kosmologiaAstrophysicsCosmology: observationdark mattergalaksijoukotpimeä ainesurveysDark energyDark matterobservations [Cosmology]dark energyObservationsLEGACY SURVEYAstrophysics of GalaxiesFísicaAstronomy and Astrophysics115 Astronomy Space scienceEVOLUTIONCosmologygalaksitGALAXIESCosmology: observations; Dark energy; Dark matter; Galaxy: formation; Large-scale structure of Universe; SurveysGalaxyformation [Galaxy]Space and Planetary ScienceGalaxy: formationcosmology: observationslarge-scale structure of Universepimeä energiaCosmology and Nongalactic Astrophysics[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct